OncoMatch/Clinical Trials/NCT07080216
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Is NCT07080216 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including ZG005 and Bevacizumab for cervical cancer.
Treatment: ZG005 · Gecacitinib · Bevacizumab — This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Cervical Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07080216 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages